Cognitive-behavioural therapy for patients with schizophrenia: A multicentre randomized controlled trial in Beijing, China

Psychological Medicine

Volumn 45, Issue 9, 2015, Pages 1893-1905

  Li, Z J ^a   Guo, Z H ^a   Wang, N ^a   Xu, Z Y ^a   Qu, Y ^b   Wang, X Q ^c   Sun, J ^d   Yan, L Q ^e   Ng, R M K ^f   Turkington, D ^g   Kingdon, D ^h  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING HUILONGGUAN HOSPITAL   (China)

^c PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^d GRIFFITH UNIVERSITY   (Australia)

^e The Third Hospital of Chaoyang District   (China)

^f KOWLOON HOSPITAL   (Hong Kong)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cognitive behavioural therapy; randomized controlled trials; schizophrenia; supportive therapy

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; CHINA; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; SOCIAL ADAPTATION; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; BEIJING; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; SCHIZOPHRENIA; SINGLE-BLIND METHOD; SOCIAL ADJUSTMENT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942881825     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291714002992     Document Type: Article

References (44)

1. Alphs L, Bossie CA, Sliwa JK, Fu DJ, Ma YW, Hulihan J (2013). Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics. Neuropsychiatric Disease and Treatment 9, 341-350.
2. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR (Text Revision). American Psychiatric Association:Washington, DC.
3. Apiquian R, Ulloa RE, Herrera-Estrella M, Moreno-Gómez A, Erosa S, Contreras V, Nicolini H (2009). Validity of the Spanish version of the Personal and Social Performance scale in schizophrenia. Schizophrenia Research 112, 181-186.
4. Brissos S, Palhav F, Marques JG, Mexia S, Carmo AL, Carvalho M, Dias C, Franco JD, Mendes R, Zuzarte P, Carita AI, Molodynski A, Figueira ML (2012). The Portuguese version of the Personal and Social Performance Scale (PSP): reliability, validity, and relationship with cognitive measures in hospitalized and community schizophrenia patients. Social Psychiatry and Psychiatric Epidemiology 47, 1077-1086.
5. Burns T, Patrick D (2007). Social functioning as an outcome measure in schizophrenia studies. Acta Psychiatrica Scandinavica 116, 403-418.
6. Citrome L, Meng X, Hochfeld M (2011). Efficacy of iloperidone in schizophrenia: A PANSS five-factor analysis. Schizophrenia Research 131, 75-81.
7. David AS (1990). Insight and psychosis. British Journal of Psychiatry: The Journal of Mental Science 156, 798-808.
8. First MB, Gibbon M (1997). User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I): Clinician Version. American Psychiatric Publishing Incorporated: Washington, DC.
9. Freeman D, Garety P, Fowler D, Kuipers E, Dunn G, Bebbington P, Hadley C (1998). The London-East Anglia randomized controlled trial of cognitive-behaviour therapy for psychosis IV: Self-esteem and persecutory delusions. British Journal of Clinical Psychology 37, 415-430.
10. Grant PM, Huh GA, Perivoliotis D, Stolar NM, Beck AT (2012). Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia. Archives of General Psychiatry 69, 121-127.
11. Jerrell JM, Hrisko S (2013). A comparison of the PANSS Pentagonal and Van der Gaag 5-factor models for assessing change over time. Psychiatry Research 207, 134-139.
12. Jiang JF, Wei JY, Bia MJ, Xu YF, Gu JY (2008). Effect of cognitive behavioral intervention on recovery of social function of patients with schizophrenic. Morden Nursing 14, 701-702 (in Chinese).
13. Kay S, Fiszbein A, Opler L (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
14. Kazantzis N, Whittington C, Dattilio F (2010). Meta-analysis of homework, effects in cognitive and behavioral therapy: A replication and extension. Clinical Psychology: Science and Practice 17, 144-156.
15. Kingdon DG, Turkington D (2004). Cognitive Therapy of Schizophrenia. Guilford Press: New York.
16. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Dixon LB (2010). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophrenia Bulletin 36, 94-103.
17. Kuipers E, Garety P, Fowler D, Freeman D, Dunn G, Bebbington P (2006). Cognitive, emotional, and social processes in psychosis: refining cognitive behavioral therapy for persistent positive symptoms. Schizophrenia Bulletin 32 (Suppl. 1), S24-S31.
18. Lysaker PH, Lancaster RS, Nees MA, Davis LW (2004). Attributional style and symptoms as predictors of social function in schizophrenia. Journal of Rehabilitation Research and Development 41, 225-232.
19. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R (2000). Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatrica Scandinavica 101, 323-329.
20. Morrison AK (2009). Cognitive behavior therapy for people with schizophrenia. Psychiatry (Edgmont) 6, 32.
21. Morrison AP, Hutton P, Wardle M, Spencer H, Barratt S, Brabban A, Callcott P, Christodoulides T, Dudley R, French P (2011). Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. Psychological Medicine 42, 1049.
22. Naeem F, Kingdon D (2011). Cognitive Therapy for Psychosis in Beijing, Cognitive Behaviour Therapy in Non Western Cultures. Nova Science Publishers: New York.
23. National Institute for Clinical Excellence (ed.) (2003). Guidelines for Psychological Treatment in Schizophrenia. Gaskell Press: London.
24. National Institute for Health and Care Excellence (2014). Psychosis and Schizophrenia in Adults: Treatment and Management. Centre for Clinical Practice at NICE: London.
25. National Institute for Health and Clinical Excellence (2009). Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care. National Collaborating Centre for Mental Health: London.
26. Ng R (2006). Cultural Adaptation of Cognitive Therapy in Hong Kong Chinese, International Handbook of Cultural Psychiatry. Taylor & Francis: London.
27. Penn DL, Meyer PS, Evans E, Wirth RJ, Cai K, Burchinal M (2009). A randomized controlled trial of group cognitive-behavioral therapy vs. enhanced supportive therapy for auditory hallucinations. Schizophrenia Research 109, 52-59.
28. Penn DL, Mueser KT, Tarrier N, Gloege A, Cather C, Serrano D, Otto MW (2004). Supportive therapy for schizophrenia. Schizophrenia Bulletin 30, 101-112.
29. Rathod S, Kingdon D, Weiden P, Turkington D (2008). Cognitive-behavioral therapy for medication-resistant schizophrenia: A review. Journal of Psychiatric Practice 14, 22-33.
30. Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, O'Carroll M, Barnes TRE (2000). A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Archives of General Psychiatry 57, 165-172.
31. Si T, Shu L, Su Y, Tian C, Yan J, Cheng J, Li X, Liu Q, Ma Y, Zhang W, Zhang H (2011). The Chinese version of the Personal and Social Performance Scale (PSP): validity and reliability. Psychiatry Research 185, 275-279.
32. Si T, Yang J, Shu L, Wang X, Kong Q, Zhou M, Li X, Liu C (2004). The reliability, validity of PANSS and its implication. Chinese Journal of Mental Health 18, 45-47.
33. Sim K, Su A, Fujii S, Yang S, Chong MY, Ungvari GS, Si T, Chung EK, Tsang HY, Chan YH (2004). Antipsychotic polypharmacy in patients with schizophrenia: A multicentre comparative study in East Asia. British Journal of Clinical Pharmacology 58, 178-183.
34. Tarrier N, Lewis S, Haddock G, Bentall RP, Drake R, Kinderman P, Kingdon D, Siddle R, Everitt J, Leadley K (2004). Cognitive-behavioural therapy in first-episode and early schizophrenia 18-month follow-up of a randomised controlled trial. British Journal of Psychiatry 184, 231-239.
35. Tarrier N, Yusupoff L, Kinney C, McCarthy E, Gledhill A, Haddock G, Morris J (1998). Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. British Medical Journal 317, 303-307.
36. Turner DT, Gaag M, Karyotaki E, Cuijpers P (2014). Psychological interventions for psychosis: A meta-analysis of comparative outcome studies. American Journal of Psychiatry 171, 523-538.
37. Velligan DI, Lam Y, Glahn DC, Barrett JA, Maples NJ, Ereshefsky L, Miller AL (2006). Defining and assessing adherence to oral antipsychotics: A review of the literature. Schizophrenia Bulletin 32, 724-742.
38. Wang CH, Li Y, Zhao Z, Pan M, Feng JG, Sun FG, Du BG (2004). Controlled study on long-term effect of cognitive behavior intervention on first episode schizophrenia. Chinese Mental Health Journal 17, 200-202.
39. Warman DM, Beck AT (2003). Cognitive behavioral therapy for schizophrenia: an overview of treatment. Cognitive and Behavioral Practice 10, 248-254.
40. Winston A, Rosenthal RN, Pinsker H (2004). Introduction to Supportive Psychotherapy. American Psychiatric Publishing Incorporated: New York.
41. World Health Organization (2011). Schizophrenia (http://www.who.int/mental-health/management/schizophrenia/en/). Accessed 19 June 2014.
42. Wykes T, Steel C, Everitt B, Tarrier N (2008). Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophrenia Bulletin 34, 523-537.
43. Xu Z, Guo ZH, Fu ZY, Wang N, Zhang Y (2013). Reliability and validity of the Chinese version of the Schedule for Assessment of Insight. Chinese Journal of Behaviour Medicine and Brain Science 22, 752-754.
44. Zuo XC, Liu SK, Yi ZY, Xie ZH, Li HD (2006). Steadystate pharmacokinetic properties of aripiprazole 10 mg PO q12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. Current Therapeutic Research, Clinical and Experimental 67, 258-269.